Balyasny Asset Management
ORMP icon

Balyasny Asset Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Balyasny Asset Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,341
Closed -$209K – 3014
2022
Q4 		$209K Buy
+17,341
New +$135K ﹤0.01% 2125
2022
Q3 		– Sell
-11,627
Closed -$53K – 3155
2022
Q2 		$53K Buy
+11,627
New +$62.1K ﹤0.01% 2352
2022
Q1 		– Sell
-21,687
Closed -$310K – 2747
2021
Q4 		$310K Buy
+21,687
New +$453K ﹤0.01% 1735

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SIGI
Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Balyasny Asset Management's ORMP Position: Q1 2023 in Review

Balyasny Asset Management sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 17,341 shares — an estimated $209K sold.

Balyasny Asset Management first reported a position in ORMP in Q4 2021 and held it in 3 quarters. The position peaked at $310K in Q4 2021. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

  • Balyasny Asset Management reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 17,341 Oramed Pharmaceuticals shares in Q1 2023, an estimated $209K.
  • Balyasny Asset Management first reported a position in Oramed Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Balyasny Asset Management's Oramed Pharmaceuticals position peaked at $310K in Q4 2021.
  • 61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.